PriceTargets.com logo

JCR Pharmaceuticals - JCRRF Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$10.11 As of 09/29/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for JCRRF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New JCR Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JCRRF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JCRRF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for JCR Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $10.11.

This chart shows the closing price for JCRRF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 2 contributing investment analysts is to moderate buy stock in JCR Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/24/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
2/6/2023CitigroupUpgradeNeutral ➝ Buy
5/26/2022CitigroupDowngradeBuy ➝ Neutral
2/25/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform
(Data available from 9/30/2018 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
JCR Pharmaceuticals logo
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
Read More

Today's Range

Now: $10.11
Low: $10.11
High: $10.11

50 Day Range

MA: $9.48
Low: $9.47
High: $10.11

52 Week Range

Now: $10.11
Low: $9.47
High: $12.38

Volume

N/A

Average Volume

250 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of JCR Pharmaceuticals?

The following sell-side analysts have issued stock ratings on JCR Pharmaceuticals in the last twelve months: Citigroup Inc., and Jefferies Financial Group Inc..
View the latest analyst ratings for JCRRF.

What is the current price target for JCR Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for JCR Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for JCR Pharmaceuticals in the next year.
View the latest price targets for JCRRF.

What is the current consensus analyst rating for JCR Pharmaceuticals?

JCR Pharmaceuticals currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for JCRRF.

What other companies compete with JCR Pharmaceuticals?

Other companies that are similar to JCR Pharmaceuticals include AstraZeneca, Cosmo Pharmaceuticals, CSPC Pharmaceutical Group, Daiichi Sankyo and Dechra Pharmaceuticals. Learn More about companies similar to JCR Pharmaceuticals.

How do I contact JCR Pharmaceuticals' investor relations team?

JCR Pharmaceuticals' physical mailing address is 3-19 Kasuga-cho, Ashiya, Hyogo 659-0021. The company's listed phone number is 81 7 9732 8591. The official website for JCR Pharmaceuticals is www.jcrpharm.co.jp. Learn More about contacing JCR Pharmaceuticals investor relations.